Third-line therapy for chronic myeloid leukemia: current status and future directions.

J Hematol Oncol · 2021 · PMC7976694 · PMID 33736651

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients with > 3 cycles of omacetaxine treatment showed a trend toward longer PFS and OS compared with the overall population, but only a small number of patients with CML-CP demonstrated durable responses.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.